


Caspofungin diacetate

Cat. No.:	HY-17006
CAS No.:	179463-17-3
Molecular Formula:	C ₅₆ H ₉₆ N ₁₀ O ₁₉
Molecular Weight:	1213.42
Target:	Fungal; Antibiotic; Bacterial
Pathway:	Anti-infection
Storage:	-20°C, sealed storage, away from moisture and light * In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)



SOLVENT & SOLUBILITY

In Vitro

H₂O : ≥ 100 mg/mL (82.41 mM)
 DMSO : 100 mg/mL (82.41 mM; Need ultrasonic)
 * "≥" means soluble, but saturation unknown.

Preparing Stock Solutions	Solvent Concentration	Mass		
		1 mg	5 mg	10 mg
	1 mM	0.8241 mL	4.1206 mL	8.2412 mL
	5 mM	0.1648 mL	0.8241 mL	1.6482 mL
	10 mM	0.0824 mL	0.4121 mL	0.8241 mL

Please refer to the solubility information to select the appropriate solvent.

In Vivo

- Add each solvent one by one: PBS
Solubility: 100 mg/mL (82.41 mM); Clear solution; Need ultrasonic
- Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline)
Solubility: ≥ 2.5 mg/mL (2.06 mM); Clear solution
- Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline
Solubility: ≥ 2.08 mg/mL (1.71 mM); Clear solution
- Add each solvent one by one: 10% DMSO >> 90% corn oil
Solubility: ≥ 2.08 mg/mL (1.71 mM); Clear solution

BIOLOGICAL ACTIVITY

Description

Caspofungin (MK-0991) diacetate is a potent antifungal agent. Caspofungin diacetate inhibits the synthesis of the fungal cell wall component β-(1,3)-D-glucan^{[1][2]}.

In Vivo

Caspofungin diacetate (1-8 mg/kg; i.p.; daily, for 7 days) is able to penetrate the CNS in mice and achieve concentrations that

result in the reduction of Candida burden in the brain^[1].

Caspofungin diacetate (0.41-41 μ M; i.p.; for 5 weeks; male C57BL/6 mice) is a safe antifungal agent at vitreal concentrations of 0.41 to 4.1 μ M in mice^[2].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Complement component 5-deficient DBA/2N mice ^[1]
Dosage:	1, 2, 4 and 8 mg/kg
Administration:	Intraperitoneal injection; daily, for 7 days
Result:	Reduced the concentration of Candida load in the brain.
Animal Model:	Male C57BL/6 mice ^[2]
Dosage:	0.41, 1.2, 2.5, 4.1, and 41 μ M
Administration:	Intraperitoneal injection; for 5 weeks
Result:	Had nonsignificant alterations in their ERG waveforms from 0.41 to 4.1 μ M.

CUSTOMER VALIDATION

- Cell Mol Immunol. 2023 Mar 2;1-14.
- EMBO Rep. 2022 Apr 11;e53932.
- Cell Physiol Biochem. 2016 Aug 12;39(3):939-949.

See more customer validations on www.MedChemExpress.com

REFERENCES

- [1]. Flattery AM, et, al. Efficacy of caspofungin in a juvenile mouse model of central nervous system candidiasis. Antimicrob Agents Chemother. 2011 Jul;55(7):3491-7.
- [2]. Mojumder DK, et, al. Evaluating retinal toxicity of intravitreal caspofungin in the mouse eye. Invest Ophthalmol Vis Sci. 2010 Nov;51(11):5796-803.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA